Luxdegalutamide, GOZETOTIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion
CJSB462B12201
Phase 2 small_molecule active
Quick answer
Luxdegalutamide, GOZETOTIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion for Metastatic castration resistant prostate cancer (mCRPC) is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Metastatic castration resistant prostate cancer (mCRPC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active